Patient Education in NorthTrondelag Hospital Trust
Patient Education in NorthTrondelag Hospital Trust - Interventions, Effects and Patient Experience
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Nord-Trondelag
-
Levanger, Nord-Trondelag, Norway, 7600
- Nord-Trondelag Hospital Trust
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosed with ICPC-2, code T89 - diabetes dependent on insulin and T90 diabetes not dependent on insulin
Exclusion Criteria:
- Diagnosed with ICPC-2, code T89 - diabetes mellitus juvenile and diabetes I
- Attended self-management program previous 12 months
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: 2
Usual care
|
|
|
Experimental: 1
Lifestyle counseling
|
Self-management group education
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
HbA1c
Time Frame: Baseline, 6, and 12 mds
|
Baseline, 6, and 12 mds
|
|
PAM - Patient activation measure
Time Frame: Baseline, 6, and 12 mds
|
Baseline, 6, and 12 mds
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
SF36
Time Frame: Baseline, 6, and 12 mds
|
Baseline, 6, and 12 mds
|
|
EQ 5D-VAS scale
Time Frame: Baseline, 6, and 12 mds
|
Baseline, 6, and 12 mds
|
|
Hunt diabetes
Time Frame: Baseline, 6, and 12 mds
|
Baseline, 6, and 12 mds
|
|
WHO-DTSQ
Time Frame: Baseline, 6, and 12 mds
|
Baseline, 6, and 12 mds
|
|
Knowledge of diabetes
Time Frame: Baseline, 6, and 12 mds
|
Baseline, 6, and 12 mds
|
|
HDL-cholesterol
Time Frame: Baseline, 6, and 12 mds
|
Baseline, 6, and 12 mds
|
|
Total cholesterol
Time Frame: Baseline, 6, and 12 mds
|
Baseline, 6, and 12 mds
|
|
Creatinin
Time Frame: Baseline, 6, and 12 mds
|
Baseline, 6, and 12 mds
|
|
Blood pressure
Time Frame: Baseline, 6, and 12 mds
|
Baseline, 6, and 12 mds
|
|
Weight
Time Frame: Baseline, 6, and 12 mds
|
Baseline, 6, and 12 mds
|
|
BMI
Time Frame: Baseline, 6, and 12 mds
|
Baseline, 6, and 12 mds
|
|
Cost/benefit
Time Frame: Baseline, 6, and 12 mds
|
Baseline, 6, and 12 mds
|
|
Triglyceride
Time Frame: Baseline, 6, and 12 mds
|
Baseline, 6, and 12 mds
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Aslak Steinsbekk, PhD, Norwegian University of Science and Technology, Trondheim, Norway
- Principal Investigator: Lisbeth O Rygg, Master, Norwegian University of Science and Technology
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- PASOPP1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.